N. Wainman

发表

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

K. Gelmon, L. Seymour, J. Lyons, 2013, Investigational New Drugs.

Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea

E. Eisenhauer, S. Gertler, G. Cairncross, 2005, Investigational New Drugs.

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma

K. Bélanger, S. Ludwin, E. Eisenhauer, 2003, Investigational New Drugs.

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

E. Eisenhauer, J. Biagi, M. Krahn, 2006, Investigational New Drugs.

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).

K. Bélanger, L. Seymour, D. Macdonald, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.

K. Bélanger, L. Seymour, L. Siu, 2002, Journal of Clinical Oncology.

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group

E. Eisenhauer, P. Forsyth, G. Cairncross, 2004, Investigational New Drugs.

Phase II study of topotecan in patients with recurrent malignant glioma

E. Eisenhauer, D. Macdonald, C. Sawka, 1996 .

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

E. Eisenhauer, K. Gelmon, M. Moore, 2003, Investigational New Drugs.

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

K. Bélanger, E. Eisenhauer, M. Smylie, 2005, Investigational New Drugs.

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly.

E. Eisenhauer, R. Donehower, A. Macleod, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

E. Eisenhauer, J. Knox, E. Winquist, 2006, Investigational New Drugs.

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.

E. Eisenhauer, A. Oza, M. Moore, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

E. Eisenhauer, S. Baruchel, M. Bernstein, 2013, Pediatric blood & cancer.

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

E. Eisenhauer, W. Walsh, A. Colevas, 2004, Investigational New Drugs.

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

E. Eisenhauer, M. Moore, C. Erlichman, 2004, Investigational New Drugs.

Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group

K. Bélanger, E. Eisenhauer, W. Steward, 2002, Investigational New Drugs.

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.

E. Eisenhauer, D. Macdonald, C. Sawka, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

K. Savage, K. Bélanger, E. Eisenhauer, 2008, Investigational New Drugs.

Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.

E. Eisenhauer, J. Johnston, P. Daeninck, 2000, Seminars in oncology.

Common toxicity criteria: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) experience

E. Eisenhauer, M. Brundage, W. Walsh, 1992 .

Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole

K. Bélanger, E. Eisenhauer, L. Whitfield, 1993, Investigational new drugs.

Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule

K. Bélanger, L. Seymour, B. Zee, 1999 .

A phase II study of foretinib in triple-negative, recurrent/metastatic breast cancer: NCIC CTG trial IND.197 (NCT01147484).

E. Eisenhauer, M. Tsao, O. Ludkovski, 2012 .

A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

E. Eisenhauer, L. Seymour, S. Gill, 2008, Investigational New Drugs.

A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium

E. Eisenhauer, S. Baruchel, M. Bernstein, 2013, Pediatric blood & cancer.

A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study

L. Seymour, B. Zee, M. Davis, 2002, Investigational New Drugs.